Inhibition of LSD1 phosphorylation alleviates colitis symptoms induced by dextran sulfate sodium
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Inflammatory Bowel Disease is caused by an acute or chronic dysfunction of the mucosal inflammatory system in the intestinal tract. In line with the results of our previous study, wherein we found that the PKC-LSD1-NF-B signaling plays a critical role in the prolonged activation of the inflammatory response, we aimed to investigate the effect of signaling on colitis in the present study. Lsd1 S112A knock-in (Lsd1SA/SA) mice, harboring a deficiency in phosphorylation by PKC, exhibited less severe colitis symptoms and a relatively intact colonic epithelial lining in dextran sulfate sodium (DSS)- induced colitis models. Additionally, a reduction in pro-inflammatory gene expression and immune cell recruitment into damaged colon tissues in Lsd1SA/SA mice was observed upon DSS administration. Furthermore, LSD1 inhibition alleviated colitis symptoms and reduced colonic inflammatory responses. Both LSD1 phosphorylation and its activity jointly play a role in the progression of DSS-induced colitis. Therefore, the inhibition of LSD1 activity could potentially protect against the colonic inflammatory response.
Abstract
Inflammatory Bowel Disease is caused by an acute or chronic dysfunction of the mucosal inflammatory system in the intestinal tract. In line with the results of our previous study, wherein we found that the PKC-LSD1-NF-B signaling plays a critical role in the prolonged activation of the inflammatory response, we aimed to investigate the effect of signaling on colitis in the present study. Lsd1 S112A knock-in (Lsd1SA/SA) mice, harboring a deficiency in phosphorylation by PKC, exhibited less severe colitis symptoms and a relatively intact colonic epithelial lining in dextran sulfate sodium (DSS)- induced colitis models. Additionally, a reduction in pro-inflammatory gene expression and immune cell recruitment into damaged colon tissues in Lsd1SA/SA mice was observed upon DSS administration. Furthermore, LSD1 inhibition alleviated colitis symptoms and reduced colonic inflammatory responses. Both LSD1 phosphorylation and its activity jointly play a role in the progression of DSS-induced colitis. Therefore, the inhibition of LSD1 activity could potentially protect against the colonic inflammatory response.
참고문헌 (36)
- Podolsky DK, "Inflammatory bowel disease", N Engl J Med, 347, pp.417~429 (2002)
- Kostić M, "Inflammatory bowel diseases(crohn’s disease and ulcerative colitis) : cost of treatment in serbia and the implications", Appl Health Econ Health Policy, 15, pp.85~93 (2016)
- 강인성, "Interferon-γ-mediated secretion of tryptophanyl-tRNA synthetases has a role in protection of human umbilical cord blood-derived mesenchymal stem cells against experimental colitis", BMB Reports, 52(5), pp.318~323 (2019), 생화학분자생물학회[DOI]
- Yu YR, "Clinical presentation of crohn’s, ulcerative colitis, and indeterminate colitis : Symptoms, extraintestinal manifestations, and disease phenotypes", Semin Pediatr Surg, 26, pp.349~355 (2017)
- Oliva-Hemker M, "Indeterminate colitis : A significant subgroup of pediatric IBD", Inflamm Bowel Dis, 12, pp.258~262 (2006)
- Alex P, "Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-Induced colitis", Inflamm Bowel Dis, 15, pp.341~352 (2009)
- Strober W, "The immunology of mucosal models of inflammation", Annu Rev Immunol, 20, pp.495~549 (2002)
- Khor B, "Genetics and pathogenesis of inflammatory bowel disease", Nature, 474, pp.307~317 (2011)
- Chassaing B, "Dextran sulfate sodium(DSS)-induced colitis in mice", Curr Protoc Immunol, 104, pp.15.25.11~15.25.14 (2014)
- Okayasu I, "A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice", Gastroenterology, 98, pp.694~702 (1990)
- Wirtz S, "Chemically induced mouse models of intestinal inflammation", Nat Protoc, 2, pp.541~546 (2007)
- Nakamura M, "Cytokine production in patients with inflammatory bowel disease", Gut, 33, pp.933~937 (1992)
- Atreya I, "NF-κB in inflammatory bowel disease", J Intern Med, 263, pp.591~596 (2008)
- Schottelius AJ, "Cytokines, NF-κB, microenvironment, intestinal inflammation and cancer", Cancer Treat Res, 130, pp.67~87 (2006)
- Viennois E, "NF-κB pathway in colitis-associated cancers", Transl Gastrointest Cancer, 2, pp.21~29 (2013)
- McDaniel DK, "Emerging roles for noncanonical NF-κB signaling in the modulation of inflammatory bowel disease pathobiology", Inflamm Bowel Dis, 22, pp.2265~2279 (2016)
- Neurath MF, "Cytokine gene transcription by NF-κB family members in patients with inflammatory bowel disease", Ann N Y Acad Sci, 859, pp.149~159 (1998)
- Kim D, "PKCα-LSD1-NF-κBsignaling cascade is crucial for epigenetic control of the inflammatory response", Mol Cell, 69, pp.398~411.e396 (2018)
- Lu T, "Regulation of NF-κB by NSD1", FBXL11-dependent reversible lysine methylation of p65, 2009, pp.107, 46~51
- Wei H, "PRMT5 dimethylates R30 of the p65 subunit to activate NF-κB", Proc Natl Acad Sci U S A, 110, pp.13516~13521 (2013)
- Culhane JC, "LSD1 and the chemistry of histone demethylation", Curr Opin Chem Biol, 11, pp.561~568 (2007)
- Shi Y, "Histone demethylation mediated by the nuclear amine oxidase homolog LSD1", Cell, 119, pp.941~953 (2004)
- Forneris F, "A highly specific mechanism of histone H3-K4 recognition by histone demethylase LSD1", J Biol Chem, 281, pp.35289~35295 (2006)
- Culhane JC, "A mechanism-based inactivator for histone demethylase LSD1", J Am Chem Soc, 128, pp.4536~4537 (2006)
- Huang J, "p53 is regulated by the lysine demethylase LSD1", Nature, 449, pp.105~108 (2007)
- 백성희, "Regulation of HIF-1α stability by lysine methylation", BMB Reports, 49(5), pp.245~246 (2016), 생화학분자생물학회
- Lee JY, "LSD1 demethylates HIF1α to inhibit hydroxylation and ubiquitin-mediated degradation in tumor angiogenesis", Oncogene, 36, pp.5512~5521 (2017)
- Peng B, "Modulation of LSD1phosphorylation by CK2", WIP1 regulates RNF168-dependent 53BP1 recruitment in response to DNA damage, 2015, pp.43, 5936~5947
- Peng B, "Phosphorylation of LSD1 by PLK1 promotes its chromatin release during mitosis", Cell Biosci, 7, pp.15~ (2017)
- Nam HJ, "Phosphorylation of LSD1 by PKCα is crucial for circadian rhythmicity and phase resetting", Mol Cell, 53, pp.791~805 (2014)
- Wirtz S, "Chemically induced mouse models of acute and chronic intestinal inflammation", Nat Protoc, 12, pp.1295~1309 (2017)
- Feng J, "Phosphorylation of LSD1 at Ser112 is crucial for its function in induction of EMT and metastasis in breast cancer", Breast Cancer Res Treat, 159, pp.443~456 (2016)
- Boulding T, "LSD1activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer", Sci Rep, 8, pp.73~ (2018)
- Farhadi A, "The role of protein kinase C isoforms in modulating injury and repair of the intestinal barrier", J Pharmacol Exp Ther, 316, pp.1~7 (2006)
- Yang GJ, "Pharmacological inhibition of LSD1 for cancer treatment", Molecules, 23, pp.3194~ (2018)
- Fu X, "Advances toward LSD1inhibitors for cancer therapy", Future Med Chem, 9, pp.1227~1242 (2017)